1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited

0719.HK
Shandong Xinhua Pharmaceutical Company LimitedHK flagHong Kong Stock Exchange
5.80
HKD
-0.13
- -
8.74BMarket Cap
Shandong Xinhua Pharmaceutical Company Limited
0719.HK
(Hong Kong Stock Exchange)

Recent

price

5.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.34
5.05
4.83
6
5.99
6
6.82
7.54
8.42
8.97
9.61
10.54
11.32
12.07
12.43
12.68
11.2
Revenue per Share
0.16
0.13
0.04
0.07
0.08
0.14
0.21
0.35
0.41
0.48
0.52
0.56
0.62
0.74
0.69
0.42
0.57
Basic EPS, GAAP
-0.07
-0.41
-0.57
-0.42
0.14
0.3
0.36
0.22
-0.1
-0.03
0.22
0.02
0.77
-0.09
0.23
0.61
-0.26
Free Cash Flow per Basic Share
0.05
0.08
0.13
0.12
0.14
0.14
0.12
0.09
0.14
0.19
0.2
0.24
0.25
0.26
0.33
0.3
0.31
Dividend per Share
1.35
1.48
1.41
1.59
1.57
1.68
1.89
2.2
2.66
3
3.36
3.75
4.01
4.44
4.75
4.83
4.4
Book Value per Share
2.47
2.63
2.46
2.84
2.67
2.82
3.05
3.77
3.98
4.32
4.71
5.12
5.85
6.38
6.83
7.05
6.44
Tangible Book Value per Share
602
581
615
566
599
600
589
599
623
625
625
622
663
671
681
690
747
Basic Weighted Avg Shares
2,614
2,938
2,972
3,391
3,590
3,597
4,015
4,516
5,245
5,606
6,006
6,560
7,503
8,101
8,466
8,755
8,373
Sales/Revenue/Turnover
6.55
5.35
1.79
1.93
3.65
4.16
5.25
7.21
8.06
9.1
9.04
7.61
7.24
7.56
7.04
5.04
6.78
Operating Margin (%)
126
134
159
191
201
228
256
283
306
345
385
439
489
517
541
588
- -
Depreciation Expense
97
76
24
39
51
83
122
210
255
300
325
349
411
497
470
290
428
Net Income, GAAP
17.87
14.58
24.92
22.42
25.31
20.15
16.83
17.5
15.62
15.28
15.68
14.04
9.68
4.99
8.8
14.66
9.86
Effective Tax Rate (%)
3.72
2.59
0.8
1.15
1.41
2.31
3.05
4.64
4.87
5.35
5.41
5.31
5.48
6.13
5.55
3.31
5.12
Profit Margin (%)
470
169
379
437
-139
-299
-560
518
20
-57
306
252
298
828
931
1,222
840
Working Capital
276
213
718
889
636
378
100
932
524
591
465
350
548
801
773
696
492
LT Debt
1,715
1,750
1,777
1,883
1,912
1,984
2,079
2,579
2,815
3,111
3,391
3,651
4,350
4,776
5,218
5,456
5,365
Total Equity
6.66
5.91
1.51
1.65
2.99
3.53
5.13
7.56
9.08
9.93
10.18
9.38
9.4
9.8
8.37
5.47
7.74
Return on Invested Capital (%)
8.58
6.61
3.45
3.63
3.65
5.44
6.37
9.38
9.63
9.75
10.31
11.01
11.26
11.92
10.11
6.08
9.31
Return on Capital (%)
12.46
9.08
2.74
4.44
5.51
8.52
11.51
17.25
17.17
17
16.36
15.72
16.46
17.61
15.13
8.83
13.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
894
1,295
959
LT Borrowings
772
398
490
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
682
690
690
Market Capitalization
3,688
3,966
4,290

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,727
3,999
3,992
Cash, Cash Equivalents & STI
1,245
1,305
1,275
Accounts Receivable, Net
868
1,200
1,096
Inventories
1,273
1,178
1,229
Total Current Liabilities
2,796
3,235
3,152
Payables & Accruals
- -
- -
- -
ST Debt
894
1,295
959
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.79%
10.08%
4.57%
Free Cash Flow
358.72%
939.51%
169.43%
Net Income, GAAP
16.86%
0.47%
-38.32%
Sales/Revenue/Turnover
9.37%
7.9%
3.41%
Total Cash Common Dividend
11.89%
11.21%
-7.11%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,475
2,258
2,002
1,732
8,466
2025
2,430
2,209
1,992
- -
8,755
2026
2,423
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
- -
- -
- -
0.69
2025
0.15
- -
- -
- -
0.42
2026
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.33
2025
- -
- -
- -
- -
0.3
2026
0.01
- -
- -
- -
- -
Similar Companies
Ovation Science Inc. (OVATF)
Green Thumb Industries Inc. (GTBIF)
Piramal Enterprises Limited (PEL.NS)
Alembic Pharmaceuticals Limited (APLLTD.NS)
Filament Health Corp. (FLHLF)
Nascent Pharma Holdings, Inc. (NASC)
Business
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) engages in the research, development, manufacture, and sale of pharmaceutical products primarily in China. The company offers a broad portfolio of products including anti-infectives such as cephalosporins, penicillins, and quinolones; cardiovascular drugs like calcium antagonists and ACE inhibitors; central nervous system medications including antidepressants and antipsychotics; and gastrointestinal agents such as proton pump inhibitors; as well as vitamins, enzymes, and biological products. It operates through segments including human antibiotics, heart & brain vessel drugs, digestive system drugs, and others, targeting hospitals, pharmacies, and distributors across mainland China with additional presence in international markets. Founded in 2004 and headquartered in Zibo, Shandong Province, China, the company maintains production facilities in multiple provinces and focuses on generic drugs alongside select innovative therapies. Shandong Xinhua Pharmaceutical serves as a key player in China's pharmaceutical industry, emphasizing cost-effective generics for essential therapeutic areas amid growing demand for affordable healthcare solutions. No major recent partnerships, acquisitions, funding rounds, or product launches have been publicly reported for the company within the last 1-2 years, reflecting stable operations in a competitive generic drug market.